Aprea Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

• Aprea Therapeutics Inc APRE.OQ reported a quarterly adjusted loss of 64 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -86 cents. The mean expectation of three analysts for the quarter was for a loss of 74 cents per share. Wall Street expected results to range from -87 cents to -62 cents per share.

• Revenue rose 11.2% to $354.62 thousand from a year ago; analysts expected $225.00 thousand.

• Aprea Therapeutics Inc's reported EPS for the quarter was a loss of 64 cents​.

• The company reported a quarterly loss of $3.78 million.

• Aprea Therapeutics Inc shares had risen by 44.7% this quarter and lost 15.3% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 15.5% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Aprea Therapeutics Inc is $16.00

This summary was machine generated from LSEG data November 8 at 04:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)